SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Sunesis Pharmaceuticals, Inc. Announces Participation in Cardiff University Sponsored Phase 2/3 Trial Evaluating Vosaroxin in Newly Diagnosed Elderly AML and High-Risk MDS Patients